Vonvendi (von willebrand factor (recombinant), vonicog alfa)
An approved treatment for Von Willebrand Disease.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify Von Willebrand factor (recombinant), vonicog alfa wherever you encounter it, plus the key facts at a glance.
- Generic name
- Von Willebrand factor (recombinant), vonicog alfa
- Brand name
- Vonvendi
- Development codes
- BAX 111, BAX111, rVWF
- Drug class
- Recombinant von Willebrand factor replacement
- Manufacturer
- Takeda Pharmaceuticals U.S.A., Inc.
- How it's taken
- IV infusion, given for bleeds, around surgery, or twice a week as prophylaxis in adults
An IV infusion of lab-made von Willebrand factor for people with von Willebrand disease.
- Its label covers treating bleeding episodes and managing bleeding around surgery in adults and children, and routine prophylaxis, regular doses to prevent bleeds, in adults only[1].
- The FDA first approved Vonvendi on December 8, 2015 for treating bleeding episodes in adults[3], and on September 5, 2025 widened its use to children and to prophylaxis in adults with any type of the disease[6].
- The FDA says it is the only recombinant, meaning not made from donated plasma, von Willebrand factor product approved in the US[6].
We'll email you when Vonvendi's FDA label changes, when the FDA acts on it, and when new trials for Von Willebrand Disease open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where Von Willebrand factor (recombinant), vonicog alfa fits
Vonvendi (vonicog alfa) is the only recombinant von Willebrand factor approved in the US, according to the FDA, and its label covers bleeding episodes and surgery in adults and children with von Willebrand disease plus routine prophylaxis in adults[6][1].
- Care for von Willebrand disease depends on its type and on a person's bleeding history, and the 2021 ASH, ISTH, NHF and WFH guidelines make recommendations on prophylaxis for frequent recurrent bleeding, desmopressin trials to decide therapy and target factor levels for major surgery[17].
- Desmopressin, sold as DDAVP Injection and Stimate nasal spray, is labeled for mild to moderate type 1 von Willebrand disease with factor VIII levels above 5% and is not indicated for severe type 1[21][22].
- Humate-P, wilate and Alphanate are plasma-derived concentrates that contain both von Willebrand factor and factor VIII.
- Humate-P is labeled for bleeds and surgery in adults and children, wilate for bleeds, surgery and routine prophylaxis in adults and children, and Alphanate for surgery in type 1 and type 2 von Willebrand disease when desmopressin does not work or cannot be used, and for minor surgery in type 3[18][19][20].
- None of these labels, nor the Vonvendi label, reports a trial comparing Vonvendi directly with a plasma-derived concentrate or with desmopressin.
- Anyone weighing Vonvendi can ask their hematologist which type of von Willebrand disease they have, whether their factor VIII level means recombinant factor VIII is needed with the first dose, and whether prophylaxis fits their bleeding history.
How Von Willebrand factor (recombinant), vonicog alfa works
Von Willebrand factor is a large, sticky blood protein. It does 2 jobs: it helps platelets stick to the wall of an injured blood vessel and to each other, and it carries factor VIII, another clotting protein, protecting it from being broken down too quickly[1]. People with von Willebrand disease have too little of it, or a form that does not work well.
MedlinePlus describes type 1 as the most common and usually mild form, type 2 as usually intermediate, and type 3, the rarest, as generally the most severe[16]. Vonvendi is von Willebrand factor made in Chinese hamster ovary cells, with no human or animal raw materials added during production[1].
Because it is not exposed to ADAMTS13, the enzyme in blood that trims the protein into shorter pieces, during manufacturing, it contains the ultra-large strands as well as the sizes normally found in plasma, and the label notes that larger strands are the most effective at supporting platelet binding[1]. Vonvendi carries only trace amounts of factor VIII[1].
Depending on a person's starting level, a single infusion is expected to raise the body's own factor VIII above 40% within 6 hours. The label calls for a separate recombinant factor VIII with the first infusion when a person's factor VIII level is below 40% or unknown, and Vonvendi alone when an immediate rise in factor VIII is not needed[1].
Side effects and safety
- Blood clots. thromboembolic events including DIC, deep vein clots, lung clots, heart attack and stroke; the risk is higher with known clotting risk factors, including low ADAMTS13 levels, and with factor VIII levels kept too high by frequent doses given with recombinant factor VIII
- Allergic and infusion reactions. including anaphylaxis, hives, swelling, chest tightness and low blood pressure; the infusion is stopped if signs of a severe allergic reaction appear
- Mouse and hamster proteins. Vonvendi contains trace amounts of mouse IgG and hamster proteins, 2ng per IU or less, and people can react to these non-human proteins; it is not used after a life-threatening reaction to Vonvendi or its ingredients
- Neutralizing antibodies. the body can make inhibitors against von Willebrand factor or factor VIII; a test is done when levels do not rise as expected or a bleed is not controlled, and Vonvendi may not work with high inhibitor levels
- Pregnancy and breastfeeding. no studies in pregnant women or animals, and no information on whether Vonvendi passes into breast milk
- Von Willebrand factor activity (VWF:RCo) and factor VIII levels, to avoid levels that stay too high
- Factor VIII levels before surgery and before repeat doses, to decide whether recombinant factor VIII is needed
- Signs of blood clots, such as pain, swelling, color change, shortness of breath, cough or coughing up blood
- An inhibitor test when expected levels are not reached or bleeding is not controlled
Vonvendi has no boxed warning[1]. Its label warns about blood clots, including DIC, deep vein clots, lung clots, heart attack and stroke, with a higher risk in people with known clotting risk factors such as low ADAMTS13 levels, and in people whose factor VIII stays too high after frequent doses given with recombinant factor VIII[1]. Allergic and infusion reactions, including anaphylaxis, can happen, and Vonvendi contains trace mouse IgG and hamster proteins that some people react to[1].
The body can also make neutralizing antibodies, called inhibitors, against von Willebrand factor or factor VIII[1]. Across 6 studies of 103 adults and 29 children with von Willebrand disease, followed for up to 4.6 years, the most common side effects were headache (14%), vomiting (7%), nausea (5%), dizziness (3%) and generalized itching (2%)[1].
High blood pressure and vertigo were each reported in 2%, and a fast heart rate, an infusion reaction with chest discomfort, a deep vein clot, hot flush, tingling at the infusion site, taste change, tremor and an ECG change were each reported once (0.8%)[1]. Since approval, allergic reactions including anaphylaxis and infusion reactions have been reported[1].
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Von Willebrand factor (recombinant), vonicog alfa
Vonvendi is a powder mixed with the supplied sterile water and given as an IV infusion, no faster than 4mL per minute, slowing or stopping if the heart races[1]. Each vial is labeled with its actual von Willebrand factor activity, nominally 650 or 1300IU[1]. For a bleed, the first dose is 40 to 50IU/kg for a minor bleed or 50 to 80IU/kg for a major one, then 40 to 50IU/kg or 40 to 60IU/kg every 8 to 24 hours as needed, about 2 to 3 days for a major bleed[1].
When factor VIII is below 40% or unknown, a recombinant factor VIII that contains no von Willebrand factor is given within 10 minutes after the first Vonvendi dose[1]. Before planned surgery, a dose may be given 12 to 24 hours ahead to let the body's factor VIII rise, with another dose within 1 hour before the procedure, and levels are checked at least every 24 hours afterward[1].
For prophylaxis in adults, the starting dose is 40 to 60IU/kg twice a week[1]. No more than 2 vials go into 1 syringe, plastic syringes are used, and mixed product is used within 3 hours[1]. Vials can be stored in the refrigerator or at room temperature up to 30°C (86°F), and must not be frozen[1].
Availability and cost
Only available as the brand-name product.
An IV clotting factor dosed by body weight and bleeding need, so the amount used varies widely from person to person. The label gives no price. Takeda Patient Support offers co-pay help for commercially insured patients and a free trial of 3 or 8 doses for new patients through its FREEDOM OF CHOICE program.
Help paying for Vonvendi
With private insurance, the drugmaker's copay card can lower what you pay for Vonvendi. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. Of the 2 charity funds for Von Willebrand Disease, 1 was open on November 16, 2026. Pick your insurance below to see which offers fit you.
- Copay help
Co-Pay Assistance Program: may cover 100% of eligible out-of-pocket costs, including deductibles and coinsurance, for commercially insured patients, up to an annual program maximum the Vonvendi page does not state. Not available to patients covered by Medicare, Medicare Advantage, Medicaid, TRICARE or other federal or state programs, Medicare Part D or in the coverage gap; FEHB is not treated as government-funded. US and territories only, 1 offer per person, cannot be combined with other coupons, free trials or patient assistance. Takeda may reduce or end help for patients in co-pay maximizer plans.
For: private insurance · source - Other support
FREEDOM OF CHOICE free trial: new (treatment-naive) Vonvendi patients with a prescription and confirmed von Willebrand disease may get 3 free doses for on-demand or surgery use in adults and children, with 2 optional ADVATE doses, or 8 free doses for adult prophylaxis. The prescriber faxes the enrollment form to 833-958-2085; TheraCom (855-776-8581) arranges delivery.
The official page does not say who qualifies. Ask the program. · source - Insurance and case manager help
Takeda Patient Support specialists answer questions and give resources; enrollment at hematologysupport.com. Phone Monday through Friday, 8 am to 8 pm ET. New patients may be able to get a Patient Starter Kit at no cost.
The official page does not say who qualifies. Ask the program. · source
Good to know: Read on vonvendi.com/vonvendi-support and the FREEDOM OF CHOICE sheet (US-XMP-0135v4.0 09/25) on November 15, 2026. The annual co-pay maximum is on takedapatientsupport.com/s/copay, which failed with a certificate error, so it is not recorded. No free-drug program for uninsured patients is named on the Vonvendi pages.
Charity funds for Von Willebrand Disease
- From a charity · Hemophilia Federation of AmericaHelping Hands Program fundOpen
Pays for: Emergency living expenses ($250 prepaid card, once per year; referral through HTC or member organization; does not cover medical bills, copays or premiums), up to $250 per year.
The foundation says: “The Helping Hands program is now open on a limited basis for 2026. Due to funding constraints, a maximum of 20 requests will be approved…”
Access and eligibility
Approved for adults and children with von Willebrand disease for on-demand treatment and control of bleeding episodes and for managing bleeding around surgery, and for routine prophylaxis in adults only[1]. The pediatric approval rests on studies that included 26 children aged 1 to 16[1]. Routine prophylaxis in children is not part of the label. Vonvendi is not used in people who have had a life-threatening allergic reaction to it or its ingredients, including hamster or mouse proteins[1].
Source: Vonvendi Patient Support
Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.
Clinical trial results
The label draws on 6 studies[1]. In the adult on-demand study (NCT01410227), 192 bleeding episodes in 22 adults, 78% of the 37 enrolled having type 3 disease, were treated, and all 18 adults in the main analysis met the treatment success goal; 97% of bleeds were rated excellent and 3% good[1][9]. In the pediatric study (NCT02932618), 18 children aged 1 to 17 had 104 bleeds treated, and 97 of the 98 bleeds with a rating were rated excellent and 1 good; 4 minor surgeries in children aged 6 to 12 were all rated excellent[1][10].
In the adult surgery study (NCT02283268), hemostasis was rated excellent or good in all 15 surgeries, 10 of them major (60% excellent, 40% good)[1][11]. In the prophylaxis study (NCT02973087), a single-arm study with no comparison group, 11 of 12 adults who had previously treated bleeds only as they happened cut their yearly rate of treated spontaneous bleeds by at least 25%, and their median yearly rate of treated bleeds, spontaneous or from injury, fell from 4.0 before the study to 0.0, and 9 of 10 adults switching from a plasma-derived von Willebrand factor kept their bleed rate at or below their past rate[1][12].
A Phase 3b continuation study in children and adults (NCT03879135) also supported the 2025 label changes[7][13].
Development history
Baxalta US Inc. filed the license application in December 2014, and the FDA approved Vonvendi on December 8, 2015 for on-demand treatment and control of bleeding episodes in adults with von Willebrand disease[3]. The FDA added the perioperative management of bleeding on April 13, 2018[4], and on January 28, 2022 added routine prophylaxis for adults with severe type 3 von Willebrand disease receiving on-demand therapy[5].
On September 5, 2025, after a Priority Review, the FDA extended routine prophylaxis to adults with all types of the disease and approved on-demand and surgical use in children, making it the first recombinant von Willebrand factor approved for children in the US[6]. The current label, revised in July 2026, names Takeda Pharmaceuticals U.S.A., Inc. as manufacturer[1]. In the EU the same medicine is sold as Veyvondi (vonicog alfa)[7].
Explore Von Willebrand Disease trials
Common questions about Von Willebrand factor (recombinant), vonicog alfa
▸What is Von Willebrand factor (recombinant), vonicog alfa (Vonvendi)?
An IV infusion of lab-made von Willebrand factor for people with von Willebrand disease. Its label covers treating bleeding episodes and managing bleeding around surgery in adults and children, and routine prophylaxis, regular doses to prevent bleeds, in adults only[1]. The FDA first approved Vonvendi on December 8, 2015 for treating bleeding episodes in adults[3], and on September 5, 2025 widened its use to children and to prophylaxis in adults with any type of the disease[6]. The FDA says it is the only recombinant, meaning not made from donated plasma, von Willebrand factor product approved in the US[6].
▸How does Von Willebrand factor (recombinant), vonicog alfa work?
Von Willebrand factor is a large, sticky blood protein. It does 2 jobs: it helps platelets stick to the wall of an injured blood vessel and to each other, and it carries factor VIII, another clotting protein, protecting it from being broken down too quickly[1]. People with von Willebrand disease have too little of it, or a form that does not work well. MedlinePlus describes type 1 as the most common and usually mild form, type 2 as usually intermediate, and type 3, the rarest, as generally the most severe[16]. Vonvendi is von Willebrand factor made in Chinese hamster ovary cells, with no human or animal raw materials added during production[1]. Because it is not exposed to ADAMTS13, the enzyme in blood that trims the protein into shorter pieces, during manufacturing, it contains the ultra-large strands as well as the sizes normally found in plasma, and the label notes that larger strands are the most effective at supporting platelet binding[1]. Vonvendi carries only trace amounts of factor VIII[1]. Depending on a person's starting level, a single infusion is expected to raise the body's own factor VIII above 40% within 6 hours. The label calls for a separate recombinant factor VIII with the first infusion when a person's factor VIII level is below 40% or unknown, and Vonvendi alone when an immediate rise in factor VIII is not needed[1].
▸What are the side effects of Von Willebrand factor (recombinant), vonicog alfa?
Vonvendi has no boxed warning[1]. Its label warns about blood clots, including DIC, deep vein clots, lung clots, heart attack and stroke, with a higher risk in people with known clotting risk factors such as low ADAMTS13 levels, and in people whose factor VIII stays too high after frequent doses given with recombinant factor VIII[1]. Allergic and infusion reactions, including anaphylaxis, can happen, and Vonvendi contains trace mouse IgG and hamster proteins that some people react to[1]. The body can also make neutralizing antibodies, called inhibitors, against von Willebrand factor or factor VIII[1]. Across 6 studies of 103 adults and 29 children with von Willebrand disease, followed for up to 4.6 years, the most common side effects were headache (14%), vomiting (7%), nausea (5%), dizziness (3%) and generalized itching (2%)[1]. High blood pressure and vertigo were each reported in 2%, and a fast heart rate, an infusion reaction with chest discomfort, a deep vein clot, hot flush, tingling at the infusion site, taste change, tremor and an ECG change were each reported once (0.8%)[1]. Since approval, allergic reactions including anaphylaxis and infusion reactions have been reported[1].
▸How is Von Willebrand factor (recombinant), vonicog alfa taken?
Vonvendi is a powder mixed with the supplied sterile water and given as an IV infusion, no faster than 4mL per minute, slowing or stopping if the heart races[1]. Each vial is labeled with its actual von Willebrand factor activity, nominally 650 or 1300IU[1]. For a bleed, the first dose is 40 to 50IU/kg for a minor bleed or 50 to 80IU/kg for a major one, then 40 to 50IU/kg or 40 to 60IU/kg every 8 to 24 hours as needed, about 2 to 3 days for a major bleed[1]. When factor VIII is below 40% or unknown, a recombinant factor VIII that contains no von Willebrand factor is given within 10 minutes after the first Vonvendi dose[1]. Before planned surgery, a dose may be given 12 to 24 hours ahead to let the body's factor VIII rise, with another dose within 1 hour before the procedure, and levels are checked at least every 24 hours afterward[1]. For prophylaxis in adults, the starting dose is 40 to 60IU/kg twice a week[1]. No more than 2 vials go into 1 syringe, plastic syringes are used, and mixed product is used within 3 hours[1]. Vials can be stored in the refrigerator or at room temperature up to 30°C (86°F), and must not be frozen[1].
▸Is Von Willebrand factor (recombinant), vonicog alfa FDA approved?
Yes. The FDA first approved Vonvendi on December 8, 2015, and its current label covers adults and children with von Willebrand disease.
Adults and children: on-demand treatment and control of bleeding episodes, and management of bleeding around surgery.
Adults only: routine prophylaxis to reduce how often bleeds happen.
Children: the 2025 pediatric approval rests on studies of children aged 1 to 16, and prophylaxis is not labeled for children.
Source: Vonvendi prescribing information
▸Can children use Vonvendi?
Yes, for treating bleeds and for surgery. The FDA approved those uses in children on September 5, 2025, the first approval of a recombinant von Willebrand factor for children in the US[6].
Not labeled: routine prophylaxis in children, which the label limits to adults.
Evidence: studies that included 26 children aged 1 to 16.
Pediatric results: of 104 bleeds treated in 18 children, 97 of the 98 with a rating were rated excellent.
▸Does Vonvendi need to be given with factor VIII?
Sometimes. The label calls for a recombinant factor VIII with the first Vonvendi dose for a bleed when a person's factor VIII level is below 40% or unknown[1].
Why: Vonvendi carries almost no factor VIII, and depending on a person's starting level, a single infusion is expected to raise the body's own factor VIII above 40% within 6 hours.
Timing: the factor VIII dose is given within 10 minutes after the Vonvendi dose.
Repeat doses: factor VIII levels are checked to decide whether more is needed.
Source: Vonvendi prescribing information
▸How is Vonvendi different from Humate-P or wilate?
Vonvendi is made in cell culture without donated plasma, while Humate-P and wilate are made from human plasma and contain both von Willebrand factor and factor VIII[1][18][19].
Factor VIII: Vonvendi has almost none, so recombinant factor VIII is added when a person's level is low.
Labeled uses: all 3 cover bleeds and surgery; wilate and Vonvendi also cover routine prophylaxis, Vonvendi in adults only.
Comparison: no head-to-head trial is reported on any of these labels.
Source: Vonvendi prescribing information
▸Is there help paying for Vonvendi?
Takeda Patient Support offers co-pay help for commercially insured patients and a free trial for new patients[14].
Co-pay: may cover 100% of eligible out-of-pocket costs up to an annual maximum that the Vonvendi page does not state; not for Medicare, Medicaid, TRICARE or other government plans.
Free trial: 3 doses for on-demand or surgery use, or 8 doses for adult prophylaxis, when a prescriber enrolls a new patient.
Phone: 1-888-229-8379, Monday through Friday, 8 am to 8 pm ET.
Source: Vonvendi Patient Support
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- Takeda Pharmaceuticals America, Inc. via DailyMed · 2026-07-28. VONVENDI (VON WILLEBRAND FACTOR (RECOMBINANT)) KIT. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53b6d198-6175-4a26-8606-dc0d2a0f12d6
- U.S. Food and Drug Administration · 2025-09-10. VONVENDI. https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/vonvendi
- U.S. Food and Drug Administration (archived) · 2015-12-08. December 8, 2015 Approval Letter. https://wayback.archive-it.org/7993/20190423064249/https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM476196.pdf
- U.S. Food and Drug Administration · 2018-04-13. April 13, 2018 Approval Letter - Vonvendi. https://www.fda.gov/media/112277/download?attachment
- U.S. Food and Drug Administration · 2022-01-28. January 28, 2022 Approval Letter - VONVENDI. https://www.fda.gov/media/155814/download?attachment
- U.S. Food and Drug Administration · 2025-09-05. FDA Approves Expanded Use of Vonvendi for von Willebrand Disease, Including for Certain Uses for Children. https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-vonvendi-von-willebrand-disease-including-certain-uses-children
- Takeda · 2025-09-05. Expanded VONVENDI Approval in Von Willebrand Disease. https://www.takeda.com/newsroom/newsreleases/2025/expanded-indication-vonvendi/
- Takeda · 2022-01-31. FDA Approves Prophylactic Treatment with VONVENDI®. https://www.takeda.com/en-us/newsroom/news-releases/2022/fda-approves-prophylactic-treatment-with-vonvendi/
- ClinicalTrials.gov. Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD). https://clinicaltrials.gov/study/NCT01410227
- ClinicalTrials.gov. A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD). https://clinicaltrials.gov/study/NCT02932618
- ClinicalTrials.gov. Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery. https://clinicaltrials.gov/study/NCT02283268
- ClinicalTrials.gov. rVWF IN PROPHYLAXIS. https://clinicaltrials.gov/study/NCT02973087
- ClinicalTrials.gov. A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD). https://clinicaltrials.gov/study/NCT03879135
- Takeda. Patient Support | VONVENDI® [von Willebrand factor (Recombinant)]. https://www.vonvendi.com/vonvendi-support
- Takeda · 2025-09. FREEDOM OF CHOICE™ Free Trial Program. https://www.shirecontent.com/HematologySupport/PDFs/VONVENDI_FOC_Info_Sheet_FOC_enrollment_form.pdf
- National Library of Medicine. Von Willebrand disease: MedlinePlus Genetics. https://medlineplus.gov/genetics/condition/von-willebrand-disease/
- Blood Advances · 2021-01-12. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.. https://pubmed.ncbi.nlm.nih.gov/33570647/
- CSL Behring GmbH via DailyMed · 2020-08-26. HUMATE-P (ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX (HUMAN)) KIT. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5f4b63b-8d8b-45b3-b530-2f1c32a1b852
- Octapharma USA Inc via DailyMed · 2026-07-16. WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) (VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)) POWDER, FOR SOLUTION. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8ef06b8-b041-054e-e58d-fd8a994a8071
- Grifols USA, LLC via DailyMed · 2026-08-28. ALPHANATE (ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX (HUMAN)) KIT. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a7aea94-654c-4113-9014-c3137de0a931
- Ferring Pharmaceuticals Inc. via DailyMed · 2022-10-03. DDAVP (DESMOPRESSIN ACETATE) INJECTION. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=651f6fee-a2c7-431b-8d5d-58b156c72244
- Ferring Pharmaceuticals Inc. via DailyMed · 2026-07-24. STIMATE (DESMOPRESSIN ACETATE) SPRAY. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5ada39c-20ed-4500-9dce-1e4ab642a358